Efficacy, Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy: a Randomized, Double-blind, Placebo Controlled, Crossover Trial
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Lacosamide (Primary)
- Indications Peripheral neuropathies
- Focus Therapeutic Use
- Acronyms LENSS; MaYa-Nav1.7
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 26 Aug 2016 Planned End Date changed from 1 Oct 2016 to 1 Mar 2017.
- 26 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2017.